Information de reference pour ce titreAccession Number: | 00004678-200107000-00039.
|
Author: | Leonid Poretsky,; Seto-Young, Donna; Shrestha, Anil; Dhillon, Sandeep; Mirjany, Mana; Liu, Hung-Ching; Yih, Melissa C; Rosenwaks, Zev
|
Institution: | Division of Endocrinology (L.P., D.S.-Y., A.S.), Beth Israel Medical Center and Albert Einstein College of Medicine, New York, New York 10003; and Division of Endocrinology (L.P., S.D., M.M.) and Center for Reproductive Medicine and Infertility (L.P., H.-C.L., M.C.Y., Z.R.), Weill Medical College of Cornell University, New York, New York 10021
|
Title: | |
Source: | Journal of Clinical Endocrinology & Metabolism. 86(7):3115-3119, July 2001.
|
Abstract: | Hyperandrogenism observed in women with a variety of insulin-resistant states is thought to be due to a stimulatory effect of insulin on ovarian steroid hormone production. However, it is not known what mechanisms could allow the ovary to remain sensitive to insulin while classical target organs for insulin action (liver, fat, and muscle) exhibit insulin resistance. One hypothesis proposed to explain this paradox suggests that a postbinding divergence of insulin receptor signaling occurs in the ovary and that signaling pathways for steroid hormone synthesis and other ovarian effects of insulin may be distinct from classical glucose signaling pathways. We now report that activation of phosphatidyl-inositol-3 (PI-3) kinase, which is crucial for glucose transport, is not necessary for the insulin-induced stimulation of progesterone production or for the insulin-induced inhibition of insulin-like growth factor binding protein 1 (IGFBP-1) production in cultured human ovarian cells.
Human granulosa cells obtained during in vitro fertilization procedures were cultured with 10, 102, 103, or 104 ng/mL insulin with or without preincubation with 100 nM wortmannin, a specific irreversible inhibitor of PI-3 kinase. IGFBP-1 concentration in the conditioned medium was measured using immunoradiometric assay or by Western blot analysis. Progesterone concentration was measured using RIA. Additional studies were carried out in cultures of human ovarian cells prepared from homogenized whole ovarian tissue of a woman with a family history of breast cancer and a mutation of BRCA-1 gene who underwent bilateral oophorectomy. These cells were cultured with 103 ng/mL insulin with or without preincubation with 100 nM wortmannin.
Two-way ANOVA was used to compare mean values of IGFBP-1 and progesterone according to insulin dose and the use of wortmannin. In cultured granulosa cell medium, progesterone production was stimulated by insulin in a dose-related manner up to 175% of control (P < 0.0001). In tissue culture medium from ovarian cells obtained from a patient with BRCA-gene mutation, concentration of progesterone in the tissue culture medium increased from 2.5 +/- 0.2 ng/mL for control to 5.4 +/- 0.3 ng/mL for cells incubated with insulin (P < 0.001). IGFBP-1 production in tissue culture medium from human granulosa cells was inhibited by insulin to the nadir of 45% of control (P < 0.0001). Preincubation with wortmannin, despite complete inhibition of PI-3 kinase in both cell systems confirmed by Western blot analysis, failed to significantly alter these results.
We conclude that inhibition of PI-3 kinase by wortmannin fails to abolish stimulatory effect of insulin on progesterone production or inhibitory effect of insulin on IGFBP-1 production in cultured human ovarian cells. These findings suggest that activation of PI-3 kinase, an enzyme crucial for insulin-stimulated glucose transport, is not necessary for the above effects of insulin in the ovary. These data provide evidence for the presence of PI-3 kinase-independent insulin signaling pathway(s) in human ovarian cells.
Copyright (C) 2001 by The Endocrine Society
|
References: | 1. Kahn CR, Flier JS, Bar RS, et al. 1976 The syndromes of insulin resistance and acanthosis nigricans: insulin-receptor disorders in man. N Engl J Med. 294:739-745.
2. Flier JS, Kahn CR, Roth J, Bar RS. 1975 Antibodies that impair insulin receptor binding in an unusual diabetic syndrome with severe insulin resistance. Science. 190:63-65.
3. Poretsky L. 1991 On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocr Rev. 12:3-13.
4. Taylor SI, Dons RF, Hernandez E, Roth J, Gorden P. 1982 Insulin resistance associated with androgen excess in women with autoantibodies to the insulin receptor. Ann Intern Med. 97:851-855.
5. Barbieri RL, Smith S, Ryan KJ. 1988 The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril. 50:197-212.
6. Poretsky L, Cataldo N, Rosenwaks Z, Guidice L. 1999 The insulin-related regulatory system in health and disease. Endocr Rev. 20:535-582.
7. White MF. 1997 The insulin signaling system and the IRS proteins. Diabetologia 40(Suppl 2):S2-S17.
8. Sakaue H, Ogawa W, Takata M, et al. 1997 Phosphoinositide 3-kinase is required for insulin-induced but not for growth hormone- or hyperosmolarity-induced glucose uptake in 3T3-L1 adipocytes. Mol Endocrinol. 11:1552-1562.
9. Gates GS, Bayer S, Seibel M, Poretsky L, Flier JS, Moses AC. 1987 Characterization of insulin-like growth factor I binding to human granulosa cells obtained during in vitro fertilization. J Recept Res. 7:885-902.
10. Poretsky L, Grigorescu F, Moses AC, Flier JS. 1985 Distribution and characterization of the insulin and IGF-I receptors in the human ovary. J Clin Endocrinol Metab. 61:728-734.
11. Bhargava G, Poretsky L, Denman H, Jandorek R, Miller L. 1989 Hormonally active long-term culture of human ovarian cells: initial characterization. Metabolism. 38:195-196.
12. Kelly KL, Ruderman NB. 1993 Insulin-stimulated phosphatidylinositol 3-kinase. Association with a 185-kDa tyrosine-phosphorylated protein (IRS-1) and localization in a low density membrane vesicle. J Biol Chem. 268:4391-4398.
13. Arcaro A, Wymann MP. 1993 Wortmannin: a potent phosphatidylinositol 3-kinase inhibitor. Biochem J. 296:297-301.
14. Imai Y, and Clemmons DR. 1999 Role of phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways in stimulation of vascular smooth muscle cell migration and deoxyribonucleic acid synthesis by insulin-like growth factor-I. Endocrinology. 140:4228-4235.
15. Zawalich WS, and Zawalich KC. 2000 A link between insulin resistance and hyperinsulinemia: inhibitor of phosphotidylinositiol 3-kinase augments glucose-induced insulin secretion from islet of lean, but not obese, rats. Endocrinology. 141:3287-3295.
16. Poretsky L, Clemons J, Bogovich K. 1992 Hyperinsulinemia and human chorionic gonadotropin synergistically promote the growth of ovarian follicular cysts in rats. Metabolism. 41:903-910.
17. Poretsky L, Piper B. 1994 Dual defect hypothesis of the polycystic ovary syndrome. Obstet Gynecol. 84:613-621.
18. Dunaif A. 1997 Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 18:774-800.
19. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. 1996 The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab. 81:3299-3306.
20. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. 1994 Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 43:647-654.
21. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. 1999 Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 340:1314-1320.
22. Nestler JE, Jakubowicz DJ. 1996 Decreases in ovarian cytochrome P450c17a activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 335:617-623.
23. Utiger RD. 1996 Insulin and the polycystic ovary syndrome. N Engl J Med. 335:657-658.
24. Poretsky L, Chandrasekher YA, Bai C, Liu HC, Rosenwaks Z, and Giudice L. 1996 Insulin receptor mediates inhibitory effect of insulin, but not of IGF-I, on insulin-like growth factor binding protein 1 (IGFBP-I) production in human granulosa cells. J Clin Endocrinol Metab. 81:493-496.
25. Willis D, Franks S. 1995 Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor. J Clin Endocrinol Metab. 8:3788-3790.
26. Nestler JE, Jakubowicz DJ, De Vargas AF, Brik C, Quintero N, Medina F. 1998 Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab. 83:2001-2005.
27. Saltiel AR. 1990 Second messengers of insulin action. Diabetes Care. 13:244-256.
28. Kaliman P, Canicio J, Shepherd P, et al. 1998 Insulin-like growth factors require phosphatidylinositol 3-kinase to signal myogenesis: dominant negative p85 expression block differentiation of L6E9 muscle cells. Mol Endocrinol. 12:85-110.
29. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT. 1995 Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev. 16:143-163.
|
Language: | English.
|
Document Type: | Original Articles.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0021-972X
|
NLM Journal Code: | hrb, 0375362
|
Annotation(s) | |
|
|